LAVAL, QC, Dec. 16, 2016 /CNW Telbec/ - ProMetic Life
Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") responded today at the request of the
Investment Industry Regulatory Organization of Canada ("IIROC") on behalf of the Toronto Stock Exchange, that it is not aware of
any undisclosed material change to the Corporation's business or operations that would cause today's movement in the Corporation's
share price and has no material change to report at this time.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a long established
biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug
development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development,
proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that
provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop
best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic
products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation
as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities
in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe, Russia, Asia and Australia.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and
successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects,
the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in
the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will
find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current
expectations in ProMetic's Annual Information Form for the year ended December 31, 2015, under the
heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking
statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes
available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All
amounts are in Canadian dollars unless indicated
otherwise.
SOURCE ProMetic Life Sciences Inc.
